Lindo has secured $2 million in matched funding through the Australian Government’s Industry Growth Program to advance the development of the Lindo Tube, an endotracheal tube embedded with antimicrobial blue light (aBL) technology.
This funding supports a total project value of $4 million and will progress the device from Technology Readiness Level 4 to 7, enabling readiness for preclinical and clinical trials in Australia and the United States.
The project is further strengthened by a strategic know-how license agreement with Mayo Clinic. Working closely with clinicians at Mayo Clinic in Jacksonville Florida, Lindo Life Science, a division of Lindo Technology Group, is advancing a proof of concept for this novel endotracheal tube. The device is designed to harness the power of antimicrobial blue light to eliminate harmful bacteria within ventilator circuits, with the goal of reducing the risk of ventilator associated pneumonia in patients requiring mechanical ventilation.
The Lindo Tube is being developed in collaboration with a respected group of partners including Marker Design, Sento Solutions, Eleven Borders, Spectral Blue, and Monash University’s Centre to Impact Antimicrobial Resistance. Together, they bring specialist expertise in design, usability, regulatory strategy, engineering, and translational research to support the device’s path to market.
“Collaborations like this are essential for translating innovation into practical medical solutions,” said Robert Gangi, CEO and Founder of Lindo. “We believe our agreement with Mayo Clinic, combined with the support of the Industry Growth Program, provides the ideal foundation to advance an Australian designed medical technology with real global potential.”
Key activities under the project include:
- Finalising the prototype and preparing for manufacture at scale
- Conducting usability studies and workflow integration testing
- Engaging early with FDA and TGA regulators
- Strengthening intellectual property and quality systems
- Building sovereign manufacturing capacity in Australia
Delivered entirely within Australia, the project is expected to support over 50 new jobs across research, development, regulatory, and advanced manufacturing. The Lindo Tube is targeting a global addressable market projected to exceed US 450 million, with initial focus on the United States and expansion opportunities across Asia Pacific and Europe.
This grant marks a critical step in advancing Lindo’s mission to deliver practical, science led infection prevention tools that strengthen critical care systems worldwide. It affirms the importance of building sovereign capability in medical device innovation and highlights the value of strategic partnerships between government, research, and industry.